7 results on '"Seaford, Emma"'
Number of results to display per page
Search Results
2. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement
- Author
-
Bomken, S, Enshaei, A, Schwalbe, E, Mikulasova, A, Dai, Y, Zaka, M, Fung, K, Bashton, M, Lim, H, Jones, L, Karataraki, N, Winterman, E, Ashby, C, Attarbaschi, A, Bertrand, Y, Bradtke, J, Buldini, B, Burke, G, Cazzaniga, G, Gohring, G, De Groot-Kruseman, H, Haferlach, C, Nigro, L, Parihar, M, Plesa, A, Seaford, E, Sonneveld, E, Strehl, S, Van der Velden, V, Rand, V, Hunger, S, Harrison, C, Bacon, C, Van Delft, F, Loh, M, Moppett, J, Vormoor, J, Walker, B, Moorman, A, Russell, L, Bomken, Simon, Enshaei, Amir, Schwalbe, Edward C, Mikulasova, Aneta, Dai, Yunfeng, Zaka, Masood, Fung, Kent Tm, Bashton, Matthew, Lim, Huezin, Jones, Lisa, Karataraki, Nefeli, Winterman, Emily, Ashby, Cody, Attarbaschi, Andishe, Bertrand, Yves, Bradtke, Jutta, Buldini, Barbara, Burke, G. A. Amos, Cazzaniga, Giovanni, Gohring, Gudrun, De Groot-Kruseman, Hesta A, Haferlach, Claudia, Nigro, Luca Lo, Parihar, Mayur, Plesa, Adriana, Seaford, Emma, Sonneveld, Edwin, Strehl, Sabine, Van der Velden, Vincent Hj, Rand, Vikki, Hunger, Stephen P, Harrison, Christine J, Bacon, Chris M, Van Delft, Frederik W, Loh, Mignon L, Moppett, John, Vormoor, Josef, Walker, Brian A, Moorman, Anthony V, Russell, Lisa J, Bomken, S, Enshaei, A, Schwalbe, E, Mikulasova, A, Dai, Y, Zaka, M, Fung, K, Bashton, M, Lim, H, Jones, L, Karataraki, N, Winterman, E, Ashby, C, Attarbaschi, A, Bertrand, Y, Bradtke, J, Buldini, B, Burke, G, Cazzaniga, G, Gohring, G, De Groot-Kruseman, H, Haferlach, C, Nigro, L, Parihar, M, Plesa, A, Seaford, E, Sonneveld, E, Strehl, S, Van der Velden, V, Rand, V, Hunger, S, Harrison, C, Bacon, C, Van Delft, F, Loh, M, Moppett, J, Vormoor, J, Walker, B, Moorman, A, Russell, L, Bomken, Simon, Enshaei, Amir, Schwalbe, Edward C, Mikulasova, Aneta, Dai, Yunfeng, Zaka, Masood, Fung, Kent Tm, Bashton, Matthew, Lim, Huezin, Jones, Lisa, Karataraki, Nefeli, Winterman, Emily, Ashby, Cody, Attarbaschi, Andishe, Bertrand, Yves, Bradtke, Jutta, Buldini, Barbara, Burke, G. A. Amos, Cazzaniga, Giovanni, Gohring, Gudrun, De Groot-Kruseman, Hesta A, Haferlach, Claudia, Nigro, Luca Lo, Parihar, Mayur, Plesa, Adriana, Seaford, Emma, Sonneveld, Edwin, Strehl, Sabine, Van der Velden, Vincent Hj, Rand, Vikki, Hunger, Stephen P, Harrison, Christine J, Bacon, Chris M, Van Delft, Frederik W, Loh, Mignon L, Moppett, John, Vormoor, Josef, Walker, Brian A, Moorman, Anthony V, and Russell, Lisa J
- Abstract
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin-MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukemia and use of individualized treatment schedules of unproven efficacy. Here we compare the molecular characteristics of these conditions and investigate historic clinical outcome data. We identified 90 cases registered in a national BCP-ALL clinical trial/registry. When present, diagnostic material underwent cytogenetic, exome, methylome and transcriptome analyses. The outcomes analyzed were 3-year event-free survival and overall survival. IG-MYC-r was identified in diverse cytogenetic backgrounds, co-existing with either established BCP-ALL-specific abnormalities (high hyperdiploidy, n=3; KMT2A-rearrangement, n=6; iAMP21, n=1; BCR-ABL1, n=1); BCL2/BCL6-rearrangements (n=15); or, most commonly, as the only defining feature (n=64). Within this final group, precursor-like V(D)J breakpoints predominated (8/9) and KRAS mutations were common (5/11). DNA methylation identified a cluster of V(D)J-rearranged cases, clearly distinct from Burkitt leukemia/lymphoma. Children with IG-MYC-r within that subgroup had a 3-year event-free survival of 47% and overall survival of 60%, representing a high-risk BCP-ALL. To develop effective management strategies this group of patients must be allowed access to contemporary, minimal residual disease-adapted, prospective clinical trial protocols.
- Published
- 2023
3. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement
- Author
-
Bomken, S, Enshaei, A, Schwalbe, E, Mikulasova, A, Dai, Y, Zaka, M, Fung, K, Bashton, M, Lim, H, Jones, L, Karataraki, N, Winterman, E, Ashby, C, Attarbaschi, A, Bertrand, Y, Bradtke, J, Buldini, B, Burke, G, Cazzaniga, G, Gohring, G, De Groot-Kruseman, H, Haferlach, C, Nigro, L, Parihar, M, Plesa, A, Seaford, E, Sonneveld, E, Strehl, S, Van der Velden, V, Rand, V, Hunger, S, Harrison, C, Bacon, C, Van Delft, F, Loh, M, Moppett, J, Vormoor, J, Walker, B, Moorman, A, Russell, L, Bomken, Simon, Enshaei, Amir, Schwalbe, Edward C, Mikulasova, Aneta, Dai, Yunfeng, Zaka, Masood, Fung, Kent Tm, Bashton, Matthew, Lim, Huezin, Jones, Lisa, Karataraki, Nefeli, Winterman, Emily, Ashby, Cody, Attarbaschi, Andishe, Bertrand, Yves, Bradtke, Jutta, Buldini, Barbara, Burke, G. A. Amos, Cazzaniga, Giovanni, Gohring, Gudrun, De Groot-Kruseman, Hesta A, Haferlach, Claudia, Nigro, Luca Lo, Parihar, Mayur, Plesa, Adriana, Seaford, Emma, Sonneveld, Edwin, Strehl, Sabine, Van der Velden, Vincent Hj, Rand, Vikki, Hunger, Stephen P, Harrison, Christine J, Bacon, Chris M, Van Delft, Frederik W, Loh, Mignon L, Moppett, John, Vormoor, Josef, Walker, Brian A, Moorman, Anthony V, Russell, Lisa J, Bomken, S, Enshaei, A, Schwalbe, E, Mikulasova, A, Dai, Y, Zaka, M, Fung, K, Bashton, M, Lim, H, Jones, L, Karataraki, N, Winterman, E, Ashby, C, Attarbaschi, A, Bertrand, Y, Bradtke, J, Buldini, B, Burke, G, Cazzaniga, G, Gohring, G, De Groot-Kruseman, H, Haferlach, C, Nigro, L, Parihar, M, Plesa, A, Seaford, E, Sonneveld, E, Strehl, S, Van der Velden, V, Rand, V, Hunger, S, Harrison, C, Bacon, C, Van Delft, F, Loh, M, Moppett, J, Vormoor, J, Walker, B, Moorman, A, Russell, L, Bomken, Simon, Enshaei, Amir, Schwalbe, Edward C, Mikulasova, Aneta, Dai, Yunfeng, Zaka, Masood, Fung, Kent Tm, Bashton, Matthew, Lim, Huezin, Jones, Lisa, Karataraki, Nefeli, Winterman, Emily, Ashby, Cody, Attarbaschi, Andishe, Bertrand, Yves, Bradtke, Jutta, Buldini, Barbara, Burke, G. A. Amos, Cazzaniga, Giovanni, Gohring, Gudrun, De Groot-Kruseman, Hesta A, Haferlach, Claudia, Nigro, Luca Lo, Parihar, Mayur, Plesa, Adriana, Seaford, Emma, Sonneveld, Edwin, Strehl, Sabine, Van der Velden, Vincent Hj, Rand, Vikki, Hunger, Stephen P, Harrison, Christine J, Bacon, Chris M, Van Delft, Frederik W, Loh, Mignon L, Moppett, John, Vormoor, Josef, Walker, Brian A, Moorman, Anthony V, and Russell, Lisa J
- Abstract
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) carries an immunoglobulin-MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukaemia and use of unproven individualised treatment schedules. Here we contrast the molecular characteristics of these conditions and investigate historic clinical outcome data. We identified 90 cases registered on a national BCP-ALL clinical trial/registry. Where present, diagnostic material underwent cytogenetic, exome, methylome and transcriptome analysis. Outcome was analysed to define 3-year event free survival (EFS) and overall survival (OS). IG-MYC-r was identified in diverse cytogenetic backgrounds, co-existing with either: established BCP-ALL specific abnormalities (high hyperdiploidy n=3, KMT2A-rearrangement n=6, iAMP21 n=1, BCR-ABL n=1); BCL2/BCL6-rearrangements (n=15); or, most commonly, as the only defining feature (n=64). Within this final group, precursor-like V(D)J breakpoints predominated (8/9) and KRAS mutations were common (5/11). DNA methylation identified a cluster of V(D)J rearranged cases, clearly distinct from Burkitt leukaemia/lymphoma. Children with IG-MYC-r within that subgroup had 3-year EFS of 47% and OS of 60%, representing a high-risk BCP-ALL. To develop effective management strategies this patient group must be allowed access to contemporary, minimal residual disease adapted, prospective clinical trial protocols.
- Published
- 2022
4. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement
- Author
-
Bomken, Simon, primary, Enshaei, Amir, additional, Schwalbe, Edward C, additional, Mikulasova, Aneta, additional, Dai, Yunfeng, additional, Zaka, Masood, additional, Fung, Kent TM, additional, Bashton, Matthew, additional, Lim, Huezin, additional, Jones, Lisa, additional, Karataraki, Nefeli, additional, Winterman, Emily, additional, Ashby, Cody, additional, Attarbaschi, Andishe, additional, Bertrand, Yves, additional, Bradtke, Jutte, additional, Buldini, Barbara, additional, Burke, GA Amos, additional, Cazzaniga, Giovanni, additional, Gohring, Gudrun, additional, De Groot-Kruseman, Hesta A, additional, Haferlach, Claudia, additional, Nigro, Luca Lo, additional, Parihar, Mayur, additional, Plesa, Adriana, additional, Seaford, Emma, additional, Sonneveld, Edwin, additional, Strehl, Sabine, additional, Van der Velden, Vincent HJ, additional, Rand, Vikki, additional, Hunger, Stephen P, additional, Harrison, Christine J, additional, Bacon, Chris M, additional, Van Delft, Frederik W, additional, Loh, Mignon L, additional, Moppett, John, additional, Vormoor, Josef, additional, Walker, Brian A, additional, Moorman, Anthony V, additional, and Russell, Lisa J, additional
- Published
- 2022
- Full Text
- View/download PDF
5. A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma (Glo-BNHL)
- Author
-
Seaford, Emma, Maycock, Shanna, Alexander, Sarah, Beishuizen, Auke, Wistinghausen, Birte, Minard-Colin, Veronique, Rigaud, Charlotte, Phillips, Charles A, Ford, James B., Kearns, Pamela R., Lawson, Anna, Williams, Ellie, Ahmed, Zahra, Muzaffar, Mahnoor, Parsons, Rhianna, Gore, Lia, Scobie, Nicole, Buenger, Victoria, Allen, Carl, Mellgren, Karin, Bollard, Catherine M., Auperin, Anne, Billingham, Lucinda, and Burke, Gladstone Austin Amos
- Published
- 2023
- Full Text
- View/download PDF
6. A Potential Paradigm for the Robust and Systematic Prioritisation of Assets in Academic-Led, Multi-Industry Collaborative Trials in Rare Populations (Glo-BNHL)
- Author
-
Seaford, Emma, Scobie, Nicole, Gore, Lia, Alexander, Sarah, Beishuizen, Auke, Wistinghausen, Birte, Minard-Colin, Veronique, Bollard, Catherine M., Mellgren, Karin, Allen, Carl, Auperin, Anne, Buenger, Victoria, Kearns, Pamela R., Lawson, Anna, Williams, Ellie, Maycock, Shanna, Ahmed, Zahra, Muzaffar, Mahnoor, Parsons, Rhianna, Billingham, Lucinda, and Burke, Gladstone Austin Amos
- Published
- 2023
- Full Text
- View/download PDF
7. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
- Author
-
Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung KTM, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GAA, Cazzaniga G, Gohring G, De Groot-Kruseman HA, Haferlach C, Nigro LL, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, Van der Velden VHJ, Rand V, Hunger SP, Harrison CJ, Bacon CM, Van Delft FW, Loh ML, Moppett J, Vormoor J, Walker BA, Moorman AV, and Russell LJ
- Subjects
- Child, Humans, Prospective Studies, Immunoglobulins genetics, Gene Rearrangement, Burkitt Lymphoma diagnosis, Burkitt Lymphoma genetics, Burkitt Lymphoma therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma diagnosis, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy
- Abstract
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin- MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukemia and use of individualized treatment schedules of unproven efficacy. Here we compare the molecular characteristics of these conditions and investigate historic clinical outcome data. We identified 90 cases registered in a national BCP-ALL clinical trial/registry. When present, diagnostic material underwent cytogenetic, exome, methylome and transcriptome analyses. The outcomes analyzed were 3-year event-free survival and overall survival. IG-MYC-r was identified in diverse cytogenetic backgrounds, co-existing with either established BCP-ALL-specific abnormalities (high hyperdiploidy, n=3; KMT2A-rearrangement, n=6; iAMP21, n=1; BCR-ABL1, n=1); BCL2/BCL6-rearrangements (n=15); or, most commonly, as the only defining feature (n=64). Within this final group, precursor-like V(D)J breakpoints predominated (8/9) and KRAS mutations were common (5/11). DNA methylation identified a cluster of V(D)J-rearranged cases, clearly distinct from Burkitt leukemia/lymphoma. Children with IG-MYC-r within that subgroup had a 3-year event-free survival of 47% and overall survival of 60%, representing a high-risk BCP-ALL. To develop effective management strategies this group of patients must be allowed access to contemporary, minimal residual disease-adapted, prospective clinical trial protocols.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.